KYIV. April 25 (Interfax-Ukraine) – PJSC Indar insulin producer (Kyiv) saw its net profit rise by 3.5 times in 2016 compared to 2015, to UAH 29.968 million.
According to a company report in the information disclosure system of the National Commission on Securities and the Stock Market, its gross profit for the year increased by 46.35%, to UAH 169.586 million, net income by 37.55%, to UAH 347.852 million.
As reported, in 2015 the manufacturer saw net profit fall by 8.8 times compared to 2014, to UAH 8.471 million.
Indar was created under a resolution of the Cabinet of Ministers in 1997 under the aegis of Kyiv meat processing plant. In 2012, the state fully reinstated its control over the enterprise which it lost in 2008 when the state stake of 70.7% belonging to Ukrmedprom was sold to Storke Holdings Limited (Belize).
